CDW Corp. vs Canopy Growth Corp — how do they compare? CDW Corp. trades at $135.37 (market cap $17.06B), while Canopy Growth Corp trades at $1 (market cap $399.40M). The key difference: CDW Corp. is far larger — about 42.7× Canopy Growth Corp's market cap, and CDW Corp. pays a 1.85% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CDW | CGC | |
|---|---|---|
Market Cap | $17.06B | $399.40M |
Sector | Technology | Health |
52-Week High | $170.77 | $1.92 |
52-Week Low | $99.30 | $0.86 |
Enterprise Value | $22.66B | $356.90M |
Dividend Yield | 1.85% | — |
Signals from Pluang's Aura AI — not financial advice
CDW trades at $135.81, down 4.34% amid margin concerns despite Q2 2026 earnings beat. The stock shows neutral technical signals with support at $134 and resistance at $139. Fundamentals remain solid with 10% revenue growth and strong ROE of 44.01%, though net margins compressed to 4.6%. Recent news highlights CFO transition plans for 2027 and continued dividend payments.
Outlook remains positive with analyst consensus at Buy (70.59%) and $148.67 price target, offering 9.5% upside. Key risks include margin pressure from hardware mix shift and elevated debt levels. AI infrastructure demand provides growth catalyst, but investors should monitor execution amid leadership changes.
CGC trades at $0.9701, up 4.07% in 24 hours, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year but continues to post net losses, with a negative net income margin of -92.38% in 2026. Cash flow trends show improving operational efficiency, though negative operating cash flow persists. Recent news highlights progress on profitability measures and anticipation of U.S. cannabis rescheduling decisions.
The outlook remains cautious due to persistent unprofitability and regulatory uncertainties, but cost-cutting and revenue growth offer potential upside. Key risks include high debt, competitive pressures, and delayed federal cannabis reforms. Analysts are divided, reflecting the stock's high-risk, high-reward profile amid ongoing turnaround efforts.
Trailing returns across standard periods
Latest headlines on both assets
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →